Literature DB >> 11113750

Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system.

G J Tarman1, C J Kane, J W Moul, J B Thrasher, J P Foley, D Wilhite, R H Riffenburgh, C L Amling.   

Abstract

OBJECTIVES: To analyze the relationships among socioeconomic status (SES), race, and the clinical parameters of patients undergoing radical prostatectomy (RP) in an equal access health care system.
METHODS: The Department of Defense Center for Prostate Disease Research longitudinal prostate cancer database from multiple military institutions was used to analyze the clinical, pathologic, and outcome data of 1058 patients with localized (Stage T2c or lower) prostate cancer and a preoperative prostate-specific antigen (PSA) level of 20 ng/mL or less who underwent RP between January 1987 and December 1997. Military rank (officer versus enlisted) was used as a surrogate measure of SES.
RESULTS: The percentage of patients with pathologic Gleason grade 7 or greater prostate cancer was higher in enlisted (45%) than in officer (37%) patients (P = 0. 021). However, no difference was found between these groups with respect to pathologic stage or biochemical recurrence rates. African Americans presented at a younger age (P = 0.003), with a higher pretreatment PSA level (P = 0.001), and demonstrated higher biochemical recurrence rates than other ethnic groups (P = 0.037). The Cox proportional hazards analysis showed that a lower SES (P = 0.010) but not African American race (P = 0.696) was an independent predictor of a higher grade (Gleason grade 7 or higher) cancer. However, biochemical progression was more common in African American men (P = 0.035) and was not related to SES (P = 0.883).
CONCLUSIONS: In an equal access health care system, patients of lower SES presented with higher grade prostate cancer at the time of RP. However, only African American race predicted biochemical progression after RP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113750     DOI: 10.1016/s0090-4295(00)00808-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  17 in total

1.  Racial Differences in Prostate Cancer Treatment: The Role of Socioeconomic Status.

Authors:  Megan Watson; David Grande; Archana Radhakrishnan; Nandita Mitra; Katelyn R Ward; Craig Evan Pollack
Journal:  Ethn Dis       Date:  2017-07-20       Impact factor: 1.847

2.  Racial/ethnic disparities in survival among men diagnosed with prostate cancer in Texas.

Authors:  Arica White; Ann L Coker; Xianglin L Du; Katherine S Eggleston; Melanie Williams
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

3.  Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Authors:  David I Chu; Daniel M Moreira; Leah Gerber; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  Cancer       Date:  2012-03-13       Impact factor: 6.860

4.  Understanding the psychosocial issues of African American couples surviving prostate cancer.

Authors:  Brian M Rivers; Euna M August; Gwendolyn P Quinn; Clement K Gwede; Julio M Pow-Sang; B Lee Green; Paul B Jacobsen
Journal:  J Cancer Educ       Date:  2012-06       Impact factor: 2.037

5.  Characteristics and outcome of prostate cancer with PSA <4 ng/ml at diagnosis: a population-based study.

Authors:  M Bonet; A Merglen; G Fioretta; E Rapiti; I Neyroud-Caspar; R Zanetti; R Miralbell; C Bouchardy
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

6.  Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients.

Authors:  Ingrid Oakley-Girvan; Laurence N Kolonel; Richard P Gallagher; Anna H Wu; Anna Felberg; Alice S Whittemore
Journal:  Am J Public Health       Date:  2003-10       Impact factor: 9.308

7.  Defining Optimal Length of Opioid Pain Medication Prescription After Common Surgical Procedures.

Authors:  Rebecca E Scully; Andrew J Schoenfeld; Wei Jiang; Stuart Lipsitz; Muhammad Ali Chaudhary; Peter A Learn; Tracey Koehlmoos; Adil H Haider; Louis L Nguyen
Journal:  JAMA Surg       Date:  2018-01-01       Impact factor: 14.766

8.  Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer.

Authors:  Laurens Holmes; Wenyaw Chan; Zhidong Jiang; Doriel Ward; E James Essien; Xianglin L Du
Journal:  Cancer Control       Date:  2009-04       Impact factor: 3.302

9.  Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room?--Results from the SEARCH database.

Authors:  Lionel L Bañez; Martha K Terris; William J Aronson; Joseph C Presti; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-31       Impact factor: 4.254

10.  Race Does Not Affect Tumor Control, Adverse Effects, or Quality of Life after Proton Therapy.

Authors:  Curtis Bryant; Bradford S Hoppe; Randal H Henderson; Romaine C Nichols; William M Mendenhall; Tamara L Smith; Christopher G Morris; Christopher R Williams; Zhong Su; Zuofeng Li; Nancy P Mendenhall
Journal:  Int J Part Ther       Date:  2017-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.